

**ENZYME
REPLACEMENT
THERAPY
(ERT)**

FOR GM1



CUREGM1
FOUNDATION

CURE GM1 HAS ENABLED THERAPEUTIC DEVELOPMENT IN GM1 GANGLIOSIDOSIS

ENZYME REPLACEMENT THERAPY IS A PROVEN MODALITY IN LYSOSOMAL STORAGE DISEASE

- 17 ERTs have been approved for 12 LSDs with a remarkably high approval rate

PROOF OF CONCEPT HAS BEEN DEMONSTRATED

- POC in two mouse models of disease
- Substrate reduction to near normal levels
- Behavioral analysis ongoing

CURE GM1 IS LAYING THE GROUNDWORK TO IND

- Have identified a high producing cell line
- Currently manufacturing at small scale; plans in place for scale-up to generate material for IND-enabling tox and the clinic
- Held FDA INTERACT meeting in 2026, a significant milestone

PROJECTED WORLDWIDE REVENUE OF \$300M-\$400M FOR GM1 ERT

SUPPORT US



GIVE TO SUPPORT
GM1 ERT

curegm1.org/donate

LEARN MORE

READ MORE ABOUT
GM1 ERT

curegm1.org/ert-project



CUREGM1
FOUNDATION